Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Pegfilgrastim + TORL-1-23 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Pegfilgrastim | Neulasta | GCSF-SD01 | Neulasta (Pegfilgrastim) is a pegylated version of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), which enhances proliferation, differentiation, and activity of neutrophils (NCI Drug Dictionary). | |
| TORL-1-23 | TORL 1-23|TORL1-23|CLDN6-23-ADC|TORL123 | CLDN6 Antibody 10 | TORL-1-23 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CLDN6 linked to monomethyl auristatin E (MMAE), which potentially inhibits growth of CLDN6-expressing tumors (PMID: 36884217). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06690775 | Phase II | Pegfilgrastim + TORL-1-23 | CATALINA-2: a Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | Recruiting | USA | ITA | IRL | FRA | DEU | CAN | BEL | AUT | AUS | 1 |